Program
JMT202
A development code. Also written as “JMT202 injection”.
Its studies are mostly in Hypertriglyceridemia, led by CSPC Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 22 open or running | phase 2since Aug 22, 2025 | Jul 10, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 10, 2024First study: phase 1 study in Healthy SubjectsFirst studyNCT06564467 · 54 planned · China
- Aug 22, 2025Phase 2 study in HypertriglyceridemiaNCT07140809 · 48 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07140809Hypertriglyceridemia · China | 2 | Recruiting | Jul 31, 2026 | 48 |
| NCT06564467Healthy Subjects · China | 1 | By invitation | Jan 10, 2025 | 54 |
How it is read
Names in the registry
- “JMT202 injection”, 1 entry
- “JMT202”, 1 entry
Codes read as this program: JMT202.
Conditions, from the studies’ own filings
- Hypertriglyceridemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.